Focus on CAR T-cells and the European consortium T2Evolve

On 4 October 2023, ART-TG and teams from Genopole’s Research Department held a microsymposium on CAR T-cells in immunotherapy. The event was open to all and underlined the place of French research in the European consortium T2Evolve. Presentations were given on the prediction of the efficacy and toxicity of CAR T-cells with ex vivo human models; the development of a cellular, antitumoral immunotherapy with IL-1RAP-targeted CAR T-cells (“bench to bedside”); the genetic engineering of lymphocytes; T2Evolve; and the role of INCa in the development of CAR T-cell therapies.